Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 30 | 2021 | 9031 | 1.320 |
Why?
|
| Radiosurgery | 13 | 2020 | 1342 | 0.960 |
Why?
|
| Spinal Neoplasms | 10 | 2024 | 716 | 0.960 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 390 | 0.920 |
Why?
|
| Radiotherapy | 4 | 2013 | 1499 | 0.660 |
Why?
|
| Meningioma | 7 | 2020 | 1218 | 0.570 |
Why?
|
| Glioma | 8 | 2019 | 3455 | 0.490 |
Why?
|
| Meningeal Neoplasms | 5 | 2021 | 1248 | 0.440 |
Why?
|
| Infratentorial Neoplasms | 1 | 2013 | 98 | 0.420 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 159 | 0.400 |
Why?
|
| SEER Program | 2 | 2013 | 1450 | 0.380 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2021 | 63 | 0.360 |
Why?
|
| Ependymoma | 1 | 2013 | 320 | 0.350 |
Why?
|
| Combined Modality Therapy | 14 | 2022 | 8529 | 0.350 |
Why?
|
| Radiation Injuries | 5 | 2020 | 1189 | 0.340 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2020 | 1784 | 0.300 |
Why?
|
| Survival Analysis | 8 | 2024 | 10090 | 0.260 |
Why?
|
| Neurofibromatosis 1 | 1 | 2011 | 561 | 0.260 |
Why?
|
| Postoperative Period | 4 | 2020 | 1813 | 0.260 |
Why?
|
| Cerebellar Neoplasms | 2 | 2022 | 586 | 0.260 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 13380 | 0.250 |
Why?
|
| Radiotherapy Dosage | 9 | 2019 | 2898 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2018 | 5315 | 0.250 |
Why?
|
| Medulloblastoma | 2 | 2022 | 678 | 0.250 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 916 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 646 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2008 | 549 | 0.230 |
Why?
|
| Melanoma | 6 | 2019 | 5709 | 0.230 |
Why?
|
| Deoxycytidine | 1 | 2008 | 877 | 0.230 |
Why?
|
| Spine | 4 | 2020 | 1118 | 0.210 |
Why?
|
| Salvage Therapy | 4 | 2018 | 1264 | 0.210 |
Why?
|
| Glioblastoma | 2 | 2018 | 3482 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2006 | 1085 | 0.210 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 21012 | 0.210 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 6346 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 782 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6935 | 0.180 |
Why?
|
| Cicatrix | 1 | 2006 | 798 | 0.170 |
Why?
|
| Immunotherapy | 5 | 2020 | 4652 | 0.170 |
Why?
|
| Middle Aged | 41 | 2024 | 220895 | 0.170 |
Why?
|
| Male | 45 | 2024 | 360804 | 0.150 |
Why?
|
| Prognosis | 12 | 2019 | 29625 | 0.150 |
Why?
|
| Neurosecretory Systems | 1 | 2019 | 223 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1626 | 0.140 |
Why?
|
| Aged | 30 | 2024 | 169289 | 0.140 |
Why?
|
| Breast | 1 | 2006 | 1967 | 0.140 |
Why?
|
| Electrons | 1 | 2018 | 265 | 0.140 |
Why?
|
| Female | 44 | 2024 | 392644 | 0.140 |
Why?
|
| Hypopituitarism | 1 | 2019 | 250 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6484 | 0.140 |
Why?
|
| Survival Rate | 7 | 2019 | 12725 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2020 | 491 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2018 | 359 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 2223 | 0.130 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 58976 | 0.130 |
Why?
|
| Humans | 62 | 2024 | 761504 | 0.130 |
Why?
|
| Methionine | 1 | 2018 | 572 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 787 | 0.130 |
Why?
|
| Adult | 30 | 2024 | 221177 | 0.120 |
Why?
|
| Retrospective Studies | 22 | 2024 | 80636 | 0.120 |
Why?
|
| Disease-Free Survival | 5 | 2022 | 6814 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 617 | 0.120 |
Why?
|
| Photons | 1 | 2018 | 589 | 0.120 |
Why?
|
| Fractures, Compression | 1 | 2016 | 131 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 220 | 0.120 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 39106 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 5671 | 0.110 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2014 | 54 | 0.110 |
Why?
|
| Ilium | 1 | 2014 | 155 | 0.110 |
Why?
|
| World Health Organization | 3 | 2015 | 1322 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 1661 | 0.110 |
Why?
|
| Credentialing | 1 | 2013 | 116 | 0.110 |
Why?
|
| Treatment Outcome | 17 | 2020 | 64680 | 0.100 |
Why?
|
| Algorithms | 3 | 2024 | 14031 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2019 | 1223 | 0.100 |
Why?
|
| Disease Progression | 9 | 2019 | 13506 | 0.100 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2011 | 21 | 0.100 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2011 | 45 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 9280 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 954 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 136 | 0.090 |
Why?
|
| Young Adult | 12 | 2022 | 59243 | 0.090 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 2557 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 1246 | 0.090 |
Why?
|
| Neurosurgical Procedures | 5 | 2020 | 2072 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11742 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 263 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2016 | 705 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1054 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 1666 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2019 | 2645 | 0.070 |
Why?
|
| Nausea | 2 | 2021 | 679 | 0.070 |
Why?
|
| Adolescent | 10 | 2022 | 88319 | 0.070 |
Why?
|
| Hippocampus | 1 | 2020 | 3766 | 0.070 |
Why?
|
| Piperidines | 1 | 2015 | 1656 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 5821 | 0.070 |
Why?
|
| Brain | 5 | 2019 | 27112 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 4511 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11118 | 0.060 |
Why?
|
| Rosaniline Dyes | 1 | 2005 | 50 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 3164 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 1324 | 0.060 |
Why?
|
| Income | 1 | 2013 | 1877 | 0.060 |
Why?
|
| Necrosis | 2 | 2019 | 1611 | 0.060 |
Why?
|
| Carcinoma, Lobular | 2 | 2005 | 481 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6485 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 629 | 0.060 |
Why?
|
| Cystectomy | 1 | 2008 | 634 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4249 | 0.060 |
Why?
|
| Nomograms | 1 | 2005 | 230 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2005 | 219 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 2057 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4876 | 0.050 |
Why?
|
| Adenoma | 1 | 2014 | 2160 | 0.050 |
Why?
|
| Disease Management | 1 | 2014 | 2508 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 13255 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2529 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2018 | 42230 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2016 | 3979 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 1972 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 4915 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 12463 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2006 | 955 | 0.050 |
Why?
|
| Anorexia | 1 | 2021 | 154 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 732 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4853 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2008 | 1824 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7390 | 0.040 |
Why?
|
| Cesium Radioisotopes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Procarbazine | 1 | 2019 | 172 | 0.040 |
Why?
|
| Lomustine | 1 | 2019 | 60 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2024 | 1638 | 0.040 |
Why?
|
| Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 2019 | 372 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7827 | 0.040 |
Why?
|
| Neoplasms | 2 | 2021 | 22170 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 18395 | 0.040 |
Why?
|
| Child | 4 | 2019 | 80153 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1745 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 350 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 288 | 0.040 |
Why?
|
| Radiography | 3 | 2014 | 6965 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 503 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2019 | 638 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 162 | 0.040 |
Why?
|
| Cognition | 1 | 2015 | 6990 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 1036 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2005 | 3466 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 651 | 0.030 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2019 | 290 | 0.030 |
Why?
|
| Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15266 | 0.030 |
Why?
|
| Risk Factors | 4 | 2019 | 74206 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2019 | 635 | 0.030 |
Why?
|
| ROC Curve | 1 | 2024 | 3579 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 1031 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2811 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 1386 | 0.030 |
Why?
|
| Time Factors | 4 | 2019 | 39967 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 571 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2014 | 154 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 41487 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1552 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 882 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2477 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 270 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 12059 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2019 | 563 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1052 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 938 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1008 | 0.030 |
Why?
|
| Groin | 1 | 2013 | 106 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2019 | 679 | 0.030 |
Why?
|
| Colitis | 1 | 2021 | 1233 | 0.030 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 231 | 0.030 |
Why?
|
| Axilla | 2 | 2005 | 624 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 6766 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2915 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 320 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1376 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3514 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1001 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1893 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1834 | 0.020 |
Why?
|
| Quality of Life | 3 | 2019 | 13367 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 598 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2425 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3595 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2019 | 54425 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 11121 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 36192 | 0.020 |
Why?
|
| Mutation | 3 | 2019 | 30052 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13639 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10766 | 0.020 |
Why?
|
| Consensus | 1 | 2017 | 3123 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1129 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2827 | 0.020 |
Why?
|
| Visual Perception | 1 | 2016 | 1387 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2011 | 798 | 0.020 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 423 | 0.020 |
Why?
|
| Learning | 1 | 2016 | 1740 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 1486 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 929 | 0.020 |
Why?
|
| Incidence | 2 | 2016 | 21353 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2011 | 980 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 2396 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2396 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 2895 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2017 | 23995 | 0.010 |
Why?
|
| Recurrence | 1 | 2017 | 8465 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2208 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2011 | 1948 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3688 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20570 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 7045 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 10209 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4740 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 3877 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10445 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20098 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 36426 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12990 | 0.010 |
Why?
|
| Pain | 1 | 2014 | 5073 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12974 | 0.010 |
Why?
|
| Massachusetts | 1 | 2011 | 8830 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 926 | 0.010 |
Why?
|
| Palliative Care | 1 | 2011 | 3598 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 9469 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168459 | 0.000 |
Why?
|
Concepts
(231)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(101)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_